KyungDong Pharm home
Prescription Medicines

Cefaclin Cap.

Product Category
Second generation cephalosporin antibiotics
Active Ingredients
cefaclor hydrate
Appearance
Hard capsule, purple at the top and white at the bottom, containing white to off-white crystalline powder.
Reimbursement Code
648101060
View Regulatory Information on the MFDS Portal ↗
1. Composition and Strength
Of 1 capsule
- Active ingredient: Cefaclor hydrate (KP) ----- 250mg (potency)
- Additives (tar coloring): Red No. 3, Blue No. 1
- Other additives: magnesium stearate, sodium starch glycolate, capsule

2. Effectiveness
○ Effective bacterial species
Streptococcus pneumoniae, Haemophilus influenzae, Staphylococcus aureus, Streptococcus pyogenes (Group A-beta-hemolytic), Escherichia coli, Proteus mirabilis, Klebsiella, and Neisseria gonorrhoeae.
○ Indications
- Otitis media
- Pneumonia, pharyngitis, tonsillitis, bronchitis
- Pyelonephritis, cystitis, gonococcal urethritis
- Swelling, carbuncle, folliculitis, cellulitis, infectious atheroma, subcutaneous abscess, raw hand, wound infection

3. Dosage and dosage
○ Adults: Cefaclor hydrate, 250 mg (potency) once orally every 8 hours. In case of severe infections (pneumonia, etc.) and infections with low susceptibility, the dose can be doubled. For acute gonococcal urethritis, administer 3g of this drug and 1g of probenecid as a single dose.
○ Children: 20 mg (potency) per kg of body weight per day, administered in divided doses every 8 hours. In case of severe infections, otitis media, and infections with low susceptibility, 40 mg (titer) per kg of body weight per day can be administered, and the maximum dose is 1 g (titer) per day.
○ Patients with impaired renal function: Can be administered without change in dosage.
Treatment of beta-hemolytic streptococcal infection should be administered for at least 10 days.

4. Precautions for use
1. Do not administer to the following patients.
1) Patients with a history of shock caused by this drug
2) Patients with a history of hypersensitivity to this drug or cephalosporin antibiotics

2. Administer with caution to the following patients.
1) Patients with a history of hypersensitivity to penicillin antibiotics
2) Patients whose parents or siblings are prone to allergic symptoms such as bronchial asthma, rash, and hives
3) Patients with severe renal impairment
4) Patients with poor oral intake or parenteral nutrition, the elderly, or patients in poor general condition (symptoms of vitamin K deficiency may appear, so observe sufficiently).
5) Patients with a history of gastrointestinal diseases (especially colitis)

3. Adverse reactions
1) Shock: Shock may occur in rare cases, so observe thoroughly and if symptoms appear, stop administration and take appropriate measures.
2) Hypersensitivity reaction: Anaphylactoid symptoms (systemic flushing, edema, difficulty breathing, angioedema, paresthesia, syncope, hypertension, vasodilatation), rash, hives, erythema, itching, fever, lymph node swelling, arthralgia, serum paralysis reaction (with or without rash, erythema multiforme, arthritis, arthralgia, fever) may occur. These symptoms and signs may appear within a few days after starting administration and end administration. It disappears within a few days. Antihistamines and corticosteroids help with recovery.
3) Skin: Stevens-Johnson syndrome and toxic epidermal necrolysis may occur, so observe thoroughly. If these symptoms appear, stop administration and take appropriate measures.
4) Blood system: Occasionally, agranulocytosis, decreased granulocytes, and rarely, decreased pancytosis, anemia, decreased platelets, increased eosinophils, increased lymphocytes, decreased leukocytes, aplastic anemia, hemolytic anemia, and reversible neutrophil decrease may occur. Therefore, sufficiently observe and take appropriate measures, such as discontinuing administration if abnormalities are recognized.
5) Liver: In rare cases, temporary hepatitis, jaundice, and sometimes elevation of AST, ALT, and ALP may occur, so observe thoroughly and discontinue administration if abnormalities appear.
6) Kidney: Severe renal disorders such as reversible interstitial nephritis, rare cases of elevated BUN, elevated serum creatinine, and acute renal failure may occur. Therefore, sufficiently observe the drug by conducting regular tests. If abnormalities are recognized, discontinue administration and take appropriate measures. Some cephalosporin antibiotics may cause seizures when administered without dose reduction, especially to patients with renal impairment. If seizures are related to drug treatment, drug treatment should be discontinued and anticonvulsants administered if clinically necessary.
7) Digestive system: In rare cases, severe colitis accompanied by bloody stool, such as pseudomembranous colitis, may occur. If abdominal pain or frequent diarrhea occurs, take appropriate measures, such as immediately discontinuing administration. Additionally, nausea, vomiting, diarrhea, abdominal pain, stomach discomfort, heartburn, and loss of appetite may sometimes occur.
8) Respiratory system: When administering other Cefem antibiotics, in rare cases, fever, cough, difficulty breathing, abnormal chest
9) Central nervous system: In rare cases, reversible hyperactivity, nervousness, anxiety, hypertonia, nervousness, insomnia, confusion, dizziness, hallucinations, drowsiness, etc. may occur.
10) Mycosis: In rare cases, stomatitis and candidiasis may occur.
11) Vitamin deficiency: In rare cases, symptoms of vitamin K deficiency (hypoprothrombinemia, bleeding tendency, etc.) and vitamin B deficiency symptoms (glossitis, stomatitis, loss of appetite, neuritis, etc.) may appear.
12) Others: In rare cases, headache, genital itching, vaginitis, vaginal moniliasis, etc. may occur.
13) Additional adverse reactions as a result of clinical trials of extended-release tablets are as follows.
Unexpected injury, loss of appetite, anxiety, joint pain, asthma, bronchitis, chest pain, chills, congestive heart failure, conjunctivitis, constipation, dizziness, menstrual pain, indigestion, dysuria, ear pain, edema, fever, abdominal distension, gastritis, infection, insomnia, vaginal discharge, rash, malaise, menstrual irregularity, muscle pain, nausea, vomiting, sore throat, nervousness, enuresis, Otitis media, pain, palpitations, difficulty breathing, sinusitis, drowsiness, sweating, tremors, hives

4. General precautions
1) When using this drug, in order to prevent the development of resistant bacteria, it is advisable to confirm sensitivity and administer only the minimum period necessary for treatment.
2) Interview sufficiently to predict reactions such as shock.
3) As with other antibiotics, the possibility of superinfection by microorganisms resistant to this drug must be considered, and in this case, an appropriate treatment must be selected.

5. Interaction
1) When co-administered with probenecid, the renal excretion rate of this drug is reduced, which may lead to sustained blood concentration.
2) When administered concurrently with nephrotoxic antibiotics or diuretics (furosemide, ethacrynic acid), renal dysfunction may increase, so administer with caution.
3) Changes in INR (international normalized ratio): An increase in anticoagulant activity has been reported in patients who received antibiotics, including this drug, simultaneously with anticoagulants. Infectious diseases (and accompanying inflammatory processes), age and general condition of the patient are risk factors. Although the interaction between this drug and warfarin has not been revealed through clinical trials, INR monitoring should be performed and, if necessary, the dose of oral anticoagulant should be adjusted appropriately. It is more severe for some classes of antibiotics, especially fluoroquinolones, macrolides, cyclins, cotrimoxazole and some cephalosporins.
4) When administered in combination with oral contraceptives, the effectiveness of contraception may be reduced, so it is advisable to additionally use another method of contraception.
5) When administered in combination with bacteriostatic antibiotics (chloramphenicol, erythromycin, tetracycline, etc.), the bactericidal effect of this drug may be reduced.

6. Administration to pregnant and lactating women
1) Since the safety of administration during pregnancy has not been established, it should be administered to pregnant women or women who may be pregnant only when the benefits of treatment are judged to outweigh the risks.
2) It has been reported that a small amount passes into breast milk, so administer with caution to nursing mothers. Small amounts of cefaclor were found in breast milk following a single 500 mg dose. The average concentration in blood was 0.18, 0.20, and 0.16 mg/L after 2, 3, and 5 hours, respectively, and became a trace amount after 1 hour. The effect of this drug on lactation is unknown, so breastfeeding women should use this drug with caution.

7. Administration to children
Efficacy and safety for newborns under 1 month of age have not been established.

8. Administration to elderly people
When administering to the elderly, keep in mind the following points and administer carefully while observing the patient's condition, paying attention to the dosage and administration interval.
1) Because physiological function is reduced, adverse reactions are likely to occur.
2) Vitamin K deficiency can also cause bleeding.

9. Effect on clinical test values
1) Be careful because false positive results may appear in urine glucose tests using Benedict's reagent, Felling's reagent, or Clini test, excluding test tape reactions.
2) Be careful because a direct Coombs test may result.

10. Other
This drug binds to certain essential proteins of the cell wall and inhibits cell wall synthesis, thereby acting as a sterilizer.

5. How to save
Store in a light-proof, airtight container at room temperature (1~30℃)

6. Packaging unit
30 capsules/bottle, 100 capsules/bottle

7. Validity period
36 months from date of manufacture

Product Updates

Total 1items

No.Product NameDetailsDate of ChangeDownload
1Cephacrine CapsulesCephacrine Capsule (efficacy, dosage, usage instructions...2004.12.23HWPCephaclean Capsule.hwp